Skip to main content

Predicant Licenses Caliper Microfluidics Technology for Proteomic Tests

NEW YORK, Jan. 6 (GenomeWeb News) - Predicant Biosciences has licensed microfluidics patents from Caliper Life Sciences for use in the analysis of proteins by mass spectrometry, the companies said today.


Under the non-exclusive licensing deal, Predicant, of South San Francisco, Calif., plans to use Caliper's microfluidics technology to separate proteins from blood for diagnostic tests based on protein patterns that it is developing.


The agreement is part of Caliper's new outlicensing strategy, "with the goal of permeating the life sciences, diagnostics and other industries with out microfluidics technologies," Caliper CEO Kevin Hrusovsky said in a company statement.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.